Inhibrx Biosciences（INBX）宣布，其用于治疗常规软骨肉瘤患者的在研药物Ozekibart的生物制品许可申请（BLA）已获得美国食品药品监督管理局（FDA）的受理。FDA的受理标志着该药物审评流程的正式启动，是向潜在获批迈出的关键一步。常规软骨肉瘤是一种罕见的骨癌，目前治疗选择有限，此次BLA的受理为患者带来了新的希望。
Inhibrx Biosciences（INBX）宣布，其用于治疗常规软骨肉瘤患者的在研药物Ozekibart的生物制品许可申请（BLA）已获得美国食品药品监督管理局（FDA）的受理。FDA的受理标志着该药物审评流程的正式启动，是向潜在获批迈出的关键一步。常规软骨肉瘤是一种罕见的骨癌，目前治疗选择有限，此次BLA的受理为患者带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.